Nuvectis Pharma Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Nuvectis Pharma Inc's ROI in the second quarter of 2026?
Nuvectis Pharma Inc recorded a cumulative net loss of $-30 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -184.25%.

Within the Healthcare sector 275 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 3826 to 4139.

Definition and Formula of Return on Investment

Select the Comparisons :

None ▼

Select the Ratio:

Return on Investment ROI▼

None ▼

Return on Investment ROI▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Investment	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Investment Change TTM	11.72 %	34.92 %	70.46 %	44.44 %	6.12 %
Y / Y Net Income Change TTM	-	-	-	-	-
Investment (TTM) in Millions	9	14	18	24	17
Return On Investment (TTM)	-184.25 %	-161 %	-143.37 %	-154.8 %	-150.04 %
NVCT's Overall Ranking	# 4139	# 3826	# 3618	# 1258	# 3401
Seq. Investment Change TTM	-10.6 %	-8.73 %	12.11 %	22.13 %	7.97 %
Seq. Net Income Change TTM	-	-	-	-	-
Net Income (TTM) in Millions	-30	-30	-29	-28	-22

NVCT Company Profile >> Back to NVCT Roi Comparisons >> See Annual NVCT Return On Investment

Return On Investment NVCT's Ranking
Within:	No.
Industry	# 113
Sector	# 276
Overall	# 4139

Return On Investment Statistics
High	Average	Low
-80.86 %	-151.13 %	-184.25 %
(Mar 31 2022)		(Jun 30 2026)

News about Nuvectis Pharma inc Return on Investment ROI

A Pioneering Advance in Oncological Pharmacology The Granting of Orphan Drug Designation for NXP800

August 29, 2024

In the evolving landscape of oncological therapeutics, the recent announcement from Nuvectis Pharma, Inc. regarding the Orphan Drug Designation granted by the venerable United States Food and Drug Administration (FDA) merits commendation and thorough examination. This notable designation pertains to NXP800, an emergent pharmacological agent designated for the treatment of malignancies characterized by a deficiency in the AT-rich interactive domain-containing protein 1a (ARID1a), specifically targeting ovarian, fallopian tube, and primary peritoneal cancers.The hallowed halls of medical discovery are often graced by compounds that illuminate the shadowy realms of ailments hitherto deemed intractable. NXP800 represents a beacon of hope for patients stricken by these malignant afflictions, which are marked by their evasiveness and the pronounced exigence of innovative therapeutic modalities. With this distinction conferred upon it, NXP800 enters a select cadre of pharmacological entities recognized for their potential to address rare and formidable conditions that have long awaited the beneficence of scientific inquiry and medical advancement.

Financial Statements
Nuvectis Pharma Inc's II. Quarter Investments	$ 9 Millions	NVCT's Balance sheet
Nuvectis Pharma Inc's II. Quarter Income	$ -7 Millions	Quarterly NVCT's Income Statement
NVCT's Income by Division		See NVCT's Income by Division

NVCT Annual Return On Investment	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2021) 2022
Total Investments in Millions	18	10	12	4	0
Y / Y Investment Growth	89.57 %	-20.39 %	187.9 %	-	-
Net Income in Millions	-29	-19	-22	-13	0
Y / Y Net Income Growth	-	-	-	-	-
Annual Return On Investment	-156.8 %	-195.61 %	-182.44 %	-304.15 %	-

Annual Roi Comment

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
NVCT's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for NVCT's Competitors
Subscribers only: Roi for Nuvectis Pharma Inc's Suppliers
Subscribers only: Return On Investment for NVCT's Customers

Other Ratios
NVCT's Roa	NVCT's Inventory Turnover Ratio	NVCT's Growth Rates	NVCT's Dividend Statistics
	NVCT's Profitability Ratios	NVCT's Asset Turnover Ratio	NVCT's Dividend Growth
NVCT's Roe	NVCT's Valuation Ratios	NVCT's Financial Strength Ratios	NVCT's Dividend Payout Ratio

Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector

ROI

Date modified: 2026-08-13T20:47:57+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.